CARDENE IV Rx
Generic Name and Formulations:
Nicardipine HCl 2.5mg/mL; soln for slow IV infusion (after dilution to 0.1mg/mL).
Chiesi USA, Inc.
Indications for CARDENE IV:
Short-term treatment of hypertension when oral therapy is not feasible or desirable.
Individualize; see full labeling.
<18yrs: not recommended.
Advanced aortic stenosis.
Cardiac failure. Angina. Acute cerebral infarction or hemorrhage. Hepatic or renal impairment. Pheochromocytoma. For caps: measure blood pressure (BP) 1–2 hrs and 8 hrs after dosing. For IV: monitor BP before and during infusion; avoid rapid or excessive reductions; switch to oral form when possible. Pregnancy (Cat.C). Nursing mothers: not recommended.
Calcium channel blocker (CCB) (dihydropyridine).
Potentiated by cimetidine. Increases serum levels of cyclosporine, tacrolimus; monitor and adjust its dose. Possibly potentiates digoxin; monitor.
Increased angina, flushing (caps), headache, pedal edema, asthenia, dizziness, somnolence (caps), tachycardia, GI upset, sweating; ECG abnormalities, orthostatic hypotension, ventricular extrasystoles, local reactions (inj).
Caps 20mg, 30mg—contact supplier; IV (10mL amps)—10; Premixed—200mL
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Predictors of Opioid Overdose in High-Risk Users
- FDA to Review Long-Acting Treatment for Opioid Use Disorder
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment
- The Fight for Patient Privacy Under Big Data Analytics